What development phase is Merital in?

Merital is FDA-approved (marketed).

What is the generic name of Merital?

NOMIFENSINE is the generic (nonproprietary) name of Merital.

Last reviewed 2026-04-20 · How we verify

Merital (NOMIFENSINE)

FDA-approved withdrawn Small molecule Quality 15/100

Nomifensine (Merital) is a marketed antidepressant that operates by increasing noradrenaline levels in the brain through the inhibition of the sodium-dependent noradrenaline transporter. Its key competitive advantage lies in its unique mechanism of action, which differentiates it from other same-class drugs such as trazodone and nefazodone. The primary risk to Nomifensine's market position is the expiration of its key composition patent in 2028, which could lead to increased competition from generics.

At a glance

Generic name	NOMIFENSINE
Drug class	nomifensine
Target	Hemoglobin HbA, Myeloperoxidase, 5-hydroxytryptamine receptor 1A
Modality	Small molecule
Therapeutic area	Nephrology
Phase	FDA-approved
First approval	1984

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
FDA label	Mechanism, indications, dosing, boxed warnings, drug interactions

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Merital CI brief — competitive landscape report
Merital updates RSS · CI watch RSS